ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19

This phase 2/3 study will evaluate the efficacy and safety of ABX464 50mg QD (oral capsule), on treating inflammation and preventing acute respiratory failure in patients infected with SARS-CoV-2. Eligible patients will be randomized according to a 2:1 ratio into 2 treatment cohorts as follows: * Standard of Care + Placebo cohort: 344 patients * Standard of Care + ABX464 50mg QD: 690 patients Study design: The study will consist of 2 periods: * Treatment phase: randomized patients will be treated for 28 days * Safety follow-up phase of 14 days after which the End of Study visit (EOS) will be performed.